First step results from a phase II study of a dendritic cell vaccine in glioblastoma patients (CombiG-vax)

BackgroundGlioblastoma (GBM) is a poor prognosis grade 4 glioma. After surgical resection, the standard therapy consists of concurrent radiotherapy (RT) and temozolomide (TMZ) followed by TMZ alone. Our previous data on melanoma patients showed that Dendritic Cell vaccination (DCvax) could increase...

Full description

Bibliographic Details

Published in:	Frontiers in Immunology
Main Authors:	Laura Ridolfi, Lorena Gurrieri, Nada Riva, Jenny Bulgarelli, Francesco De Rosa, Massimo Guidoboni, Valentina Fausti, Nicoletta Ranallo, Sebastiano Calpona, Marcella Tazzari, Massimiliano Petrini, Anna Maria Granato, Elena Pancisi, Flavia Foca, Monia Dall’Agata, Isabella Bondi, Elena Amadori, Pietro Cortesi, Chiara Zani, Valentina Ancarani, Alessandro Gamboni, Antonio Polselli, Giuseppe Pasini, Daniela Bartolini, Giuseppe Maimone, Donatella Arpa, Luigino Tosatto
Format:	Article
Language:	English
Published:	Frontiers Media S.A. 2024-08-01
Subjects:	glioblastoma vaccine immunotherapy dendritic cell adoptive cell therapy radiochemotherapy
Online Access:	https://www.frontiersin.org/articles/10.3389/fimmu.2024.1404861/full